Inflammasome's Time Has Come, Says Ex-GSK NodThera Chief After £28m Financing

CSO and acting CEO of UK-Based biotech outlines to Scrip plans to develop next generation NLRP3 inflammasome inhibitors to treat diseases driven by chronic inflammation.

Coins
CEO Says NodThera Now Has Funding To Move Into The Clinic • Source: Shutterstock

Having successfully closed a Series A financing for £28m, NodThera can now begin progressing molecules aimed at reducing chronic inflammation, known to be the root cause of a many diseases such as metabolic disorders, cancer and CNS diseases such as Alzheimer’s disease, the British biotech's chief science officer and acting CEO told Scrip.

"We'll use these funds to bring forward our preclinical drugs to target the inflammasome in inflammatory disease and they should...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.